Shaaltiel Yoseph 4
4 · Protalix BioTherapeutics, Inc. · Filed Aug 9, 2010
Insider Transaction Report
Form 4
Shaaltiel Yoseph
DirectorExecutive VP, R&D
Transactions
- Sale
Common Stock
2010-08-05$7.00/sh−48,408$338,856→ 768,373 total - Sale
Common Stock
2010-08-06$7.00/sh−4,619$32,333→ 763,754 total
Footnotes (1)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.